1. Porter PL. Global trends in breast cancer incidence and mortality. Salud Pública Méx. 2009;51(Suppl 2): s141-6. https://doi.org/10.1590/s0036-36342009000800003.
2. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res. 1999; 1(1): 14-7. https://doi.org/10.1186/bcr6.
3. Fan S, Yang Z, Ke Z, Huang K, Liu N, Fang X, et al. Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother. 2017; 95:1636-43. https://doi.org/10.1016/j.biopha.2017.09.076.
4.Berruti A, Brizzi MP, Generali D, Ardine M, Dogliotti L, Bruzzi P, et al. Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist.2008; 13(11):1137-48. https://doi.org/10.1634/theoncologist.2008-0162.
5. Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene. 2001;273(1):1-11. https://doi.org/10.1016/S0378-1119(01)00551-0.
6. Ghosh SK, Gadiparthi L, Zeng ZZ, Bhanoori M, Tellez C, et al. ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells. J Biol Chem.2002;277(24): 21325-31. https://doi.org/10.1074/jbc.M201608200.
7. Laag E, Majidi M, Cekanova M, Masi T, Takahashi T, Schuller HM. NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer. 2006; 119(7): 1547-52. https://doi.org/10.1002/ijc.21987.
8. Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, McConkey DJ, et al. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene. 2000;19(22): 2721-30. https://doi.org/10.1038/sj.onc.1203569.
9. Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U. ATF3 and stress responses. Gene Expr.1999;7:321-35.
10. Thompson MR, Xu D, Williams BR. ATF3 transcription factor and its emerging roles in immunity and cancer.J Mol Med (Berl).2009;87(11):1053-60. https://doi.org/10.1007/s00109-009-0520-x.
11. Zhou H, Li N, Yuan Y, Jin YG, Guo H, Deng W, et al. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target. Basic Res Cardiol. 2018;113(5):37. https://doi.org/10.1007/s00395-018-0698-6.
12. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000; 6(5):1099-108. https://doi.org/10.1016/S1097-2765(00)00108-8.
13. Kim P, Scott MR, Meador-Woodruff JH. Dysregulation of the unfolded protein response (UPR) in the dorsolateral prefrontal cortex in elderly patients with schizophrenia. Mol Psychiatry. 2021;26(4):1321-31. https://doi.org/10.1038/s41380-019-0537-7.
14. Xiao L, Rao JN, Zou T, Liu L, Marasa BS, Chen J, et al. Polyamines regulate the stability of activating transcription factor-2 mRNA through RNA-binding protein HuR in intestinal epithelial cells. Mol Biol Cell. 2007;18(11):4579-90. https://doi.org/10.1111/j.1365-2966.2004.08045.x.
15. Chüeh AC, Tse JWT, Dickinson M, Ioannidis P, Jenkins L, Togel L, et al. ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types. Clin Cancer Res. 2017;23(18):5573-84. https://doi.org/10.1158/1078-0432.CCR-17-0466.
16. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1): w98-102. https://doi.org/10.1093/nar/gkx247.
17. Asplund A, Edqvist PHD, Schwenk JM, Pontén F. Antibodies for profiling the human proteome—The Human Protein Atlas as a resource for cancer research. Proteomics. 2012;12(13):2067-77. https://doi.org/10.1002/pmic.201100504.
18. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-10. https://doi.org/ 10.1093/nar/30.1.207.
19. von Eschenbach AC, Buetow K. Cancer informatics vision: CaBIG. Cancer Inform. 2007; 2:22-4. https://doi.org/10.1177/117693510600200013.
20. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.Cancer Discov. 2012; 2(5):401-4. https://doi.org/10.1158/2159-8290.CD-12-0095.
21. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. https://doi.org/ 10.1126/scisignal.2004088.
22. Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, et al. CancerSEA: A cancer single‑cell state atlas. Nucleic Acids Res. 2019; 47 (D1): D900‑8. https://doi.org/ 10.1093/nar/gky939.
23. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature.2012;486 (7403):346-52. https://doi.org/0.1038/nature10983.
24. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121-32. https://doi.org/10.1016/j.ccr.2006.01.013.
25. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res.2009;11(1): R7. https://doi.org/10.1186/bcr2222.
26. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci. 2005;102(31)11005-10. https://doi.org/10.1016/S0304-4017(96)01026-6.
27. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, et al. Single-cell RNA-seq enables comprehensive tumor and immune cell profiling in primary breast cancer. Nat Commun.2017; 8: 15081. https://doi.org/10.1038/ncomms15081.
28. Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature,2016; 537(7618): 102-6. https://doi.org/10.1038/nature19328.
29. Sakamoto K, Karelina K, Obrietan K. CREB: a multifaceted regulator of neuronal plasticity and protection. J Neurochem. 2011;116(1): 1-9. https://doi.org/10.1111/j.1471-4159.2010.07080.x.
30. Lopez-Bergami P, Lau E, Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer. 2010;10(1):65-76. https://doi.org/10.1038/nrc2846.
31. Watson G, Ronai Z, Lau E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol Res. 2017; 119:347-57. https://doi.org/10.1016/j.phrs.2017.02.004.
32. Ghosh SK, Gadiparthi L, Zeng ZZ, Bhanoori M, Tellez C, Bar-Eli M, et al. ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells. J Biol Chem. 2002;277(24): 21325-31. https://doi.org/10.1074/jbc.M201608200.
33. Laag E, Majidi M, Cekanova M, Masi T, Takahashi T, Schuller HM. NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer.2006;119(7): 1547-52. https://doi.org/10.1002/ijc.21987.
34. Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, McConkey DJ, et al. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene. 2000;19(22): 2721-30. https://doi.org/ 10.1038/sj.onc.1203569.
35. Wang H, Zhu Y, Chen H, Yang N, Wang X, Li B, et al. Colorectal cancer risk variant rs7017386 modulates two oncogenic lncRNAs expression via ATF1-mediated long-range chromatin loop. Cancer Lett. 2021;518: 140-51. https://doi.org/ 10.1016/j.canlet.2021.07.021.
36. Decker AM, Decker JT, Jung Y, Cackowski FC, Daignault-Newton S, Morgan TM, et al. Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer Through Upregulation of GAS6. Transl Oncol. 2020;13(7): 100781. https://doi.org/10.1016/j.tranon.2020.100781.
37. Panza E, Ozenberger BB, Straessler KM, Barrott JJ, Li L, Wang Y, et al. The clear cell sarcoma functional genomic landscape. J Clin Invest. 2021;131(15). https://doi.org/10.1172/JCI146301.
38. Houvras Y, Benezra M, Zhang H, Manfredi JJ, Weber BL, Licht JD. BRCA1 physically and functionally interacts with ATF1. J Biol Chem. 2000;275(46):36230-7. https://doi.org/10.1074/jbc.M002539200.
39. Jones DT, Lechertier T, Mitter R, Herbert JM, Bicknell R, Jones JL et al. Gene expression analysis in human breast cancer associated blood vessels. PLoS One. 2012;7(10):e44294. https://doi.org/10.1371/journal.pone.0044294.
39. Lopez-Bergami P, Lau E, Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer. 2010;10(1):65-76.https://doi.org/ 10.1038/nrc2681.
40. Liu Y, Wang Y, Li W, Zheng P, Liu Y. Activating transcription factor 2 and c-Jun-mediated induction of FoxP3 for experimental therapy of mammary tumor in the mouse. Cancer Res. 2009;69(14):5954-60. https://doi.org/10.1158/0008-5472.CAN-09-0778.
41. Maekawa T, Shinagawa T, Sano Y, Sakuma T, Nomura S, Nagasaki K et al. Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol. 2007;27(5):1730-44. https://doi.org/10.1128/MCB.01579-06.
42. Tsuchimochi K, Otero M, Dragomir CL, Plumb DA, Zerbini LF, Libermann TA et al. GADD45beta enhances Col10a1 transcription via the MTK1/MKK3/6/p38 axis and activation of C/EBPbeta-TAD4 in terminally differentiating chondrocytes. J Biol Chem. 2010;285(11):8395-407. https://doi.org/10.1074/jbc.M109.038638.
43. Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res. 2010;70(9):3494-504. https://doi.org/10.1158/0008-5472.CAN-09-3251.
44. van Dam H, Castellazzi M. Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis. Oncogene. 2001;20(19):2453-64. https://doi.org/10.1038/sj.onc.1204239.
45. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002;277(21):18649-57. https://doi.org/10.1074/jbc.M111415200.
46. Knippen S, Loning T, Muller V, Schroder C, Janicke F, Milde-Langosch K. Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. Anticancer Res. 2009;29(1):183-9.
47. Su B, Tang HL, Deng M, Liao QJ, Zeng X, Zhang WL et al. Stage-associated dynamic activity profile of transcription factors in nasopharyngeal carcinoma progression based on protein/DNA array analysis. OMICS. 2011;15(1-2):49-60. https://doi.org/10.1089/omi.2010.0055.
48. Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V. The role of ATF-2 in oncogenesis. Bioessays. 2008;30(4):314-27. https://doi.org/10.1002/bies.20734.
49. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A. 1991;88(9):3720-4. https://doi.org/10.1073/pnas.88.9.3720.
50. Hai TW, Liu F, Coukos WJ, Green MR. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev. 1989;3(12B):2083-90. https://doi.org/ 10.1101/gad.3.12b.2083.
51. Hsu JC, Laz T, Mohn KL, Taub R. Identification of LRF-1, a leucine-zipper protein that is rapidly and highly induced in regenerating liver. Proc Natl Acad Sci U S A. 1991;88(9):3511-5. https://doi.org/10.1073/pnas.88.9.3511.
52. Nilsson M, Toftgard R, Bohm S. Activated Ha-Ras but not TPA induces transcription through binding sites for activating transcription factor 3/Jun and a novel nuclear factor. J Biol Chem. 1995;270(20):12210-8. https://doi.org/10.1074/jbc.270.20.12210.
53. Hai T, Wolford CC, Chang YS. ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Expr. 2010;15(1):1-11. https://doi.org/10.3727/105221610x12819686555015.
54. Lu D, Wolfgang CD, Hai T. Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem. 2006;281(15):10473-81. https://doi.org/10.1074/jbc.M509278200.
55. Borgoni S, Sofyali E, Soleimani M, Wilhelm H, Muller-Decker K, Will R et al. Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. Cancers (Basel). 2020;12(10). https://doi.org/10.3390/cancers12102918.
56. Middleton JD, Stover DG, Hai T. Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response. Int J Mol Sci. 2018;19(11). https://doi.org/10.3390/ijms19113333.
57. Yan L, Della Coletta L, Powell KL, Shen J, Thames H, Aldaz CM et al. Activation of the canonical Wnt/beta-catenin pathway in ATF3-induced mammary tumors. PLoS One. 2011;6(1):e16515. https://doi.org/10.1371/journal.pone.0016515.
58. Yin X, Wolford CC, Chang YS, McConoughey SJ, Ramsey SA, Aderem A et al. ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci. 2010;123(Pt 20):3558-65. https://doi.org/10.1242/jcs.064915.
59. Cao H, Yang ZX, Jiang GQ. Expression and clinical significance of activating transcription factor 3 in human breast cancer. Iran J Basic Med Sci. 2013;16(11):1151-4.
60. Zhao W, Sun M, Li S, Chen Z, Geng D. Transcription factor ATF3 mediates the radioresistance of breast cancer. J Cell Mol Med. 2018;22(10):4664-75. https://doi.org/10.1111/jcmm.13688.
61. Hasim MS, Nessim C, Villeneuve PJ, Vanderhyden BC, Dimitroulakos J. Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer. Transl Oncol. 2018;11(4):988-98. https://doi.org/10.1016/j.tranon.2018.06.001.
62. Yin X, Dewille JW, Hai T. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene. 2008;27(15):2118-27. https://doi.org/10.1038/sj.onc.1210861.
63. Wortel IMN, van der Meer LT, Kilberg MS, van Leeuwen FN. Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells. Trends Endocrinol Metab. 2017;28(11):794-806. https://doi.org/10.1016/j.tem.2017.07.003.
64. Nagelkerke A, Bussink J, Mujcic H, Wouters BG, Lehmann S, Sweep FC et al. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast Cancer Res. 2013;15(1):R2. https://doi.org/10.1186/bcr3373.
65. Dey S, Sayers CM, Verginadis, II, Lehman SL, Cheng Y, Cerniglia GJ et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J Clin Invest. 2015;125(7):2592-608. https://doi.org/10.1172/JCI78031.
66. Fan CF, Mao XY, Wang EH. Elevated p-CREB-2 (ser 245) expression is potentially associated with carcinogenesis and development of breast carcinoma. Mol Med Rep. 2012;5(2):357-62. https://doi.org/10.3892/mmr.2011.657.
67. Gonzalez-Gonzalez A, Munoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M et al. Activating Transcription Factor 4 Modulates TGFbeta-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res. 2018;24(22):5697-709. https://doi.org/10.1158/1078-0432.CCR-17-3125.
68. Snezhkina AV, Kudryavtseva AV, Kardymon OL, Savvateeva MV, Melnikova NV, Krasnov GS et al. ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells. Oxid Med Cell Longev. 2019;2019:6175804. https://doi.org/10.1155/2019/6175804.
69. Bai X, Ni J, Beretov J, Wasinger VC, Wang S, Zhu Y et al. Activation of the eIF2alpha/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis. Redox Biol. 2021; 43:101993. https://doi.org/10.1016/j.redox.2021.101993.
70. Angelastro JM. Targeting ATF5 in Cancer. Trends Cancer. 2017;3(7):471-4. https://doi.org/10.1016/j.trecan.2017.05.004.
71. Hu M, Wang B, Qian D, Li L, Zhang L, Song X, et al. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis. Anticancer Res. 2012;32(10):4385-94.
72. Ishihara S, Yasuda M, Ishizu A, Ishikawa M, Shirato H, Haga H. Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells. Oncotarget. 2015;6(7):4602-14. https://doi.org/10.18632/oncotarget.2912.
73. Persengiev SP, Green MR. The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis. 2003;8(3):225-8. https://doi.org/10.1023/a:1023633704132.
74. Ben-Shmuel S, Rashed R, Rostoker R, Isakov E, Shen-Orr Z, LeRoith D. Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. Front Endocrinol (Lausanne). 2017; 8:173. https://doi.org/10.3389/fendo.2017.00173.
75. Li G, Li W, Angelastro JM, Greene LA, Liu DX. Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells. Mol Cancer Res. 2009;7(6):933-43. https://doi.org/10.1158/1541-7786.MCR-08-0365.
76. Dluzen D, Li G, Tacelosky D, Moreau M, Liu DX. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner. J Biol Chem. 2011;286(9):7705-13. https://doi.org/10.1074/jbc.M110.207639.
77. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer. 2007;120(9):1883-90. https://doi.org/10.1002/ijc.22469.
78. Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer. Cell. 2017;168(4):692-706. https://doi.org/10.1016/j.cell.2016.12.004.
79. Madden E, Logue SE, Healy SJ, Manie S, Samali A. The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance. Biol Cell. 2019;111(1):1-17. https://doi.org/10.1111/boc.201800050.
80. McGrath EP, Logue SE, Mnich K, Deegan S, Jager R, Gorman AM et al. The Unfolded Protein Response in Breast Cancer. Cancers (Basel). 2018;10(10) : 344. https://doi.org/10.3390/cancers10100344.
81. Wu J, Rutkowski DT, Dubois M, Swathirajan J, Saunders T, Wang J et al. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev Cell. 2007;13(3):351-64. https://doi.org/10.1016/j.devcel.2007.07.005.
82. Sicari D, Fantuz M, Bellazzo A, Valentino E, Apollonio M, Pontisso I et al. Mutant p53 improves cancer cells' resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene. 2019;38(34):6184-95. https://doi.org/10.1038/s41388-019-0878-3.
83. Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M. Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol. 2002;22(18):6321-35. https://doi.org/10.1128/MCB.22.18.6321-6335.2002.
84. Gozdecka M, Breitwieser W. The roles of ATF2 (activating transcription factor 2) in tumorigenesis. Biochem Soc Trans. 2012;40(1):230-4. https://doi.org/10.1042/BST20110630.
85. Goetz J, Chatton B, Mattei MG, Kedinger C. Structure and expression of the ATFa gene. J Biol Chem. 1996;271(47):29589-98. https://doi.org/10.1074/jbc.271.47.29589.
86. De Graeve F, Bahr A, Sabapathy KT, Hauss C, Wagner EF, Kedinger C et al. Role of the ATFa/JNK2 complex in Jun activation. Oncogene. 1999;18(23):3491-500. https://doi.org/10.1038/sj.onc.1202723.
87. Song F, Wei M, Wang J, Liu Y, Guo M, Li X et al. Hepatitis B virus-regulated growth of liver cancer cells occurs through the microRNA-340-5p-activating transcription factor 7-heat shock protein A member 1B axis. Cancer Sci. 2019;110(5):1633-43. https://doi.org/10.1111/cas.14004.
88. Guo HQ, Ye S, Huang GL, Liu L, Liu OF, Yang SJ. Expression of activating transcription factor 7 is correlated with prognosis of colorectal cancer. J Cancer Res Ther. 2015;11(2):319-23. https://doi.org/10.4103/0973-1482.148688.